China embarks on clinical trial for virus vaccine


BEIJING: China has started the first phase of a clinical trial for a Covid-19 (coronavirus) vaccine, records show, as the world's scientists race to find a way to combat the deadly pathogen.

It comes after US health officials said last week they had started a trial to evaluate a possible vaccine in Seattle.

The Chinese effort began on March 16 -- the same day as the US announcement -- and is expected to continue until the end of the year, according to a filing in the country's Clinical Trial Registry, dated March 17.

"Volunteers of the Covid-19 phase one trial have already started receiving the vaccine," a staff member involved in the government-funded project said on Sunday.

The 108 participants, aged between 18 and 60, will be tested in three groups and given different dosages. They are all residents of the central city of Wuhan -- where the new coronavirus first emerged late last year.

As the Covid-19 pandemic rages and governments step up protection measures, pharmaceutical companies and research labs around the world are working at full tilt.

There are currently no approved vaccines or medication for the new disease, which has killed more than 13,000 people worldwide so far.

The vaccine trial announcements come amid an escalating feud between the US and China over the pandemic, with President Donald Trump enraging Beijing by speaking of the "Chinese virus".

China's Global Times published an opinion piece last week noting "the development of a vaccine is a battle that China cannot afford to lose".

But the quest is expected to take time -- the US candidate vaccine may take another year to 18 months before becoming available.

An antiviral treatment called remdesivir, made by US-based Gilead Sciences, is already in the final stages of clinical trials in Asia and doctors in China have reported it has proven effective in fighting the disease.

But only randomised trials will allow scientists to know for sure if it really helps or whether patients would have recovered without it. - AFP

Get 20% OFF The Star Digital Access

Monthly Plan

RM 13.90/month

RM 11.12/month

Billed as RM 11.12 for the 1st month, RM 13.90 thereafter.

Best Value

Annual Plan

RM 12.33/month

RM 9.87/month

Billed as RM 118.40 for the 1st year, RM 148 thereafter.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!
China , Testing , Covid-19 Vaccine

Next In Regional

Indonesia to establish national peatland, mangrove agency to curb recurring fires
Taxi driver killed, 11 others injured as vehicle hits Discovery Bay bus and truck
TikTok darling and Cambodia's famous daughter Princess Norodom Jenna will headline the opening ceremony of the Asean Hyundai Cup
Trump touts Iran inspection deal as Tehran disputes claim
9.3 million�illicit cigarettes seized by Customs
Japan 'robot wolves' in high demand to scare off bears
Lula won’t sideline China or anyone in rare earths, tells Trump refining stays in Brazil
Asean still not ready to accept Myanmar leaders at summits, meetings, says Tok Mat
Anwar holds bilateral talks with S'pore, Laos counterparts
Asean vows to avoid export bans, share fuel as oil prices soar

Air Pollutant Index

Note: API is calculated based on 24hr running average of the most dominant parameter.

Highest API Readings

    Select State and Location to view the latest API reading

    Others Also Read